Home › Sjögren's Disease › New York
Sjögren's Disease clinical trials in New York
3 studies for Sjögren's Disease are looking for participants at sites in New York.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03816345Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- St Lawrence Health System, Potsdam
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07621809A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- New York University, Brooklyn
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07041099From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.